Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development
Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics
Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales.
HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026.
'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.'
'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.'
About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system.
About Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact info@PercheronTx.com.
CONTACT: Hummingbird Bioscience Media Contact: Crystal Ho c.ho@hummingbirdbio.com media@hummingbirdbio.com +65 6979 5580 Hummingbird Bioscience Investor Contact: investors@hummingbirdbio.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
30 minutes ago
- Bloomberg
China Credit ETFs to Almost Double as Funds Rush to Tech Bonds
The number of corporate bond exchange-traded funds in China is set to almost double to 21 as a growing number of money managers draw up strategies to invest in the fledgling tech-related bond market. Ten Chinese firms including E Fund Management Co., China Southern Asset Management Co. and Invesco Great Wall Fund Management Co., have submitted applications to the securities regulator to set up ETFs that will invest in notes that fund technology businesses, state media reported last week. Brokerage Huaxi Securities Co. says there are currently 11 corporate bond ETFs in China.
Yahoo
an hour ago
- Yahoo
Xiaomi Launches YU7 SUV, Undercuts Tesla's Model Y With 200,000 Orders in 3 Minutes
Xiaomi unveiled its YU7 electric SUV on Thursday, pricing it at 253,500 yuan ($35,364)about 4% below Tesla's (TSLA, Financials) Model Y in China. The company said it received 200,000 orders within three minutes of launch. With a top range of 835 km, the YU7 beats the Model Y's 719 km and marks Xiaomi's most aggressive move in the EV space. CEO Lei Jun aims to position the vehicle as a direct rival to Tesla, following strong sales of Xiaomi's SU7 sedan. The company raised its 2025 delivery target to 350,000 units and is expanding its EV infrastructure in Beijing. Analysts say the YU7 could help Xiaomi transition from a tech-first brand to a mass-market EV player. This article first appeared on GuruFocus.
CBS News
an hour ago
- CBS News
North Korea set to open its biggest tourist site, though it still largely blocks foreigners
North Korea next week will open a signature coastal tourist site that it says will usher in a new era in its tourism industry, though there is no word on when the country will fully reopen to foreign visitors. The Wonsan-Kalma coastal tourist zone has hotels and other accommodations for nearly 20,000 guests who can swim in the sea, engage in sports and recreation activities and eat at restaurants and cafeterias on site, state media said. North Korean leader Kim Jong Un toured the site and cut the inaugural tape at a lavish ceremony Tuesday, the official Korean Central News Agency reported Thursday. Kim said its construction would be recorded as "one of the greatest successes this year" and called the site "the proud first step" toward realizing the government's policy of developing tourism, according to KCNA. In this photo provided by the North Korean government, North Korean leader Kim Jong Un, second right, with his daughter, left, cuts the inaugural tape during a completion ceremony of the Wonsan-Kalma coastal tourist zone in North Korea Tuesday, June 24, 2025. Independent journalists were not given access to cover the event depicted in this image distributed by the North Korean government. The content of this image is as provided and cannot be independently verified. Korean language watermark on image as provided by source reads: "KCNA" which is the abbreviation for Korean Central News Agency. Korean Central News Agency/Korea News Service via AP North Korea will open the site to domestic tourists first The Wonsan-Kalma beach resort is North Korea's biggest tourist site. KCNA said North Korea will begin service for domestic tourists next Tuesday. It didn't say when North Korea will start receiving foreign tourists, but Russian officials said later Thursday that the first Russian tour to the site will happen in July. Observers say the resort likely required a huge investment from North Korea's limited budget, so it eventually will have to accept Chinese and other foreign tourists too to break even. Kim has been pushing to make the country a tourism hub as part of efforts to revive the ailing economy, and the Wonsan-Kalma zone is one of his most talked-about tourism projects. KCNA reported North Korea will confirm plans to build large tourist sites in other parts of the country, too. But North Korea hasn't fully lifted a ban on foreign tourists that it imposed in early 2020 to guard against the COVID-19 pandemic. Experts say North Korea has been slow to resume its international tourism because of remaining pandemic curbs, a flare-up of tensions with the U.S. and South Korea in recent years and worries about Western tourists spreading a negative image of its system. In this photo provided by the North Korean government, North Korean leader Kim Jong Un, sitting center, with his wife Ri Sol Ju, rear, and daughter tours the Wonsan-Kalma coastal tourist zone in North Korea Tuesday, June 24, 2025. Independent journalists were not given access to cover the event depicted in this image distributed by the North Korean government. The content of this image is as provided and cannot be independently verified. Korean language watermark on image as provided by source reads: "KCNA" which is the abbreviation for Korean Central News Agency. Korean Central News Agency/Korea News Service via AP Russian tourists expected soon Russia's Primorsky region, which borders North Korea, said that the first group of Russian tourists to the resort will depart on July 7. The region's press service said that during their eight-day trip, Russian tourists will also have an opportunity to visit major attractions in Pyongyang, the North Korean capital, according to Russian state news agency Tass. Starting from February 2024, North Korea has already been accepting Russian tourists to other areas amid the booming military and other partnerships between the two countries, but Chinese group tours, which made up more than 90% of visitors before the pandemic, remain stalled. In February this year, a small group of international tourists visited North Korea for the first time in five years, but tourist agencies said in March that their tours to North Korea were paused. Kim's recent foreign policy prioritizes relations with Russia as he's been supplying troops and conventional weapons to support its war against Ukraine in return for economic and military assistance. But North Korea's ties with China, which has long been its biggest trading partner and aid benefactor, have apparently cooled as China is reluctant to join an anti-Western alliance with North Korea and Russia, analysts say. Tuesday's ceremony that marked the completion of the resort's construction drew the Russian ambassador to North Korea and his embassy staff, KCNA said. But it didn't say whether any Chinese diplomats were also invited. "There seems to be issues that North Korea hasn't yet resolved in its relations with China. But North Korea has put in too much money on tourism and plans to spend more. Subsequently, to get its money's worth, North Korea can't help receiving Chinese tourists," Lee Sangkeun, an expert at the Institute for National Security Strategy, a think tank run by South Korea's intelligence agency. Lim Eul-chul, a professor at Kyungnam University's Institute for Far Eastern Studies in Seoul, also said that foreign tourism to the Wonsan-Kalma site will begin with Russians. But he said Chinese tours to the zone, a sort of civilian exchange, will also begin soon, adding bilateral trade between China and North Korea has been recovering. South Korean and American tours won't likely happen soon Lim said that South Korean and American tours to North Korea won't likely restart anytime soon, though both new liberal South Korean President Lee Jae Myung and U.S. President Trump have expressed hopes to revive dialogue with North Korea. In January, when Mr. Trump boasted about his ties with Kim, he said "I think he has tremendous condo capabilities. He's got a lot of shoreline," a likely reference to Wonsan-Kalma. North Korea hasn't publicly responded to Mr. Trump's outreach. It has repeatedly rejected Washington and Seoul's dialogue offers and focused on expanding its nuclear weapons program since Kim's high-stakes nuclear diplomacy with Mr. Trump collapsed in 2019.
